Payors Need Robust Review Processes to Prepare for Wave of Digital Therapeutics
Digital therapeutics are gaining momentum. As such, payors need to keep an eye on product approvals and pending legislation, and develop a robust process for how such products will be considered for their formularies and covered, speakers said during AMCP 2023.
